OBN’s Corporate Membership of 400-plus organisations includes many R&D companies (therapeutic, medical technology and diagnostics) as well as an extensive range of contract research (CRO) and manufacturing (CMO) organisations, companies in the associated industries and specialists suppliers.
The membership breakdown by sector can be accessed by clicking on the down arrow on the right of the search box.
Search for companies by:
- Sector/Subsector using the dropdown box below
- Keyword search using the box on the right
- Alphabetical listing
Please note that only details of current OBN Members appear here.
Manentia LtdManentia LtdClinical development for new drugs, diagnostics, medical devices and other novel medical innovationsContact: David Fleet
We are experts in clinical development for new drugs, diagnostics, medical devices and other medical innovations.
We specialise in taking an innovation all the way to marketed product covering every development step through out the process.
Our extensive expertise covers planning, conducting and reporting of each step whilst adding maximum value to the offering as development progresses.
We have a highly experienced team of professionals covering key aspects of the development process from Investment, Drug Management, Site Selection/Management, Medical Management to Regulatory Affairs, Statistical Design/Analysis, and Quality, ensuring our clients receive an unrivalled standard of service
This means we can help clients take their drugs to market in the most efficient manner, ensuring minimum development time and ultimately leading to maximum profit and return for investors
We Have Extensive Experience In:
Drugs From Large Range Of Therapeutic Areas Ranging From CNS, Oncology, Cardiovascular, Arthritis, Anti-Inflammatory And Pain
Biologics/Biosimilars – Particularly Endocrine
Diagnostics/Biomarkers – Alzheimer’s Diseas
Medical Devices – Imaging/Implants
Other Novel Medical Innovations – Video Games
Stem Cell – Macular Degeneration/ Thoracic Support
Vaccines – Alzheimer’s Disease
MitoDys TherapeuticsMitoDys TherapeuticsMitoDys Therapeutics has developed an innovative drug discovery approach, informed by both biological complexity and chemical promiscuity, that aims to mine the complex diseased networks underlying Parkinson’s disease
MitoDys Therapeutics has developed an innovative drug discovery approach, informed by both biological complexity and chemical promiscuity, that aims to mine the complex diseased networks underlying Parkinson’s and discover therapeutic agents, repurposed and novel, that can significantly affect the course of the disease, and improve the quality of life of afflicted patients .